These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 22383232

  • 1. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C, Tintoré M, Vidal-Jordana A, Castilló J, Galán I, Río J, Arrambide G, Comabella M, Arévalo MJ, Horno R, Vicente MJ, Caminero A, Nos C, Sastre-Garriga J, Montalban X.
    Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 4. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 29; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 6. Advances in the management of PML: focus on natalizumab.
    Fox R.
    Cleve Clin J Med; 2011 Nov 29; 78 Suppl 2():S33-7. PubMed ID: 22123933
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct 29; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 8. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
    Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC.
    Mult Scler; 2011 Feb 29; 17(2):151-6. PubMed ID: 21078695
    [Abstract] [Full Text] [Related]

  • 9. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 29; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 10. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2014 Jan 29; 20(1):108-11. PubMed ID: 23828867
    [Abstract] [Full Text] [Related]

  • 11. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.
    Eur J Neurol; 2016 Jun 29; 23(6):1079-85. PubMed ID: 27018481
    [Abstract] [Full Text] [Related]

  • 12. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug 29; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

  • 13. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA, Puccio LM, Brydon EW.
    J Neurol; 2010 Jun 29; 257(6):954-8. PubMed ID: 20052484
    [Abstract] [Full Text] [Related]

  • 14. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS.
    Mult Scler; 2012 Aug 29; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract] [Full Text] [Related]

  • 15. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 29; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 16. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Jun 29; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 17. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL.
    Acta Neurol Scand; 2017 Nov 29; 136 Suppl 201():37-44. PubMed ID: 29068484
    [Abstract] [Full Text] [Related]

  • 18. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J, Berthele A, Kümpfel T, Krumbholz M, Jochim A, Kronsbein H, Ryschkewitsch C, Jensen P, Lippmann K, Hemmer B, Major E, Hohlfeld R.
    Mult Scler; 2013 Aug 29; 19(9):1213-5. PubMed ID: 23124790
    [Abstract] [Full Text] [Related]

  • 19. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
    Correia I, Jesus-Ribeiro J, Batista S, Martins AI, Nunes C, Macário MC, Cunha L, Sousa L.
    J Clin Neurosci; 2017 Nov 29; 45():257-260. PubMed ID: 28844615
    [Abstract] [Full Text] [Related]

  • 20. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov 29; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.